Page 19 - 《中国药房》2025年16期

of imipenem/cilastatin and meropenem in critically ill the better? Defining the optimal beta-lactam target for
adult patients[J]. J Glob Antimicrob Resist，2024，36： critically ill patients to reach infection resolution and im‐
252-259. prove outcome[J]. J Intensive Care，2020，8（1）：86.
[34] CHUA N G，LOO L，HEE D K H，et al. Therapeutic drug [45] CAO H W，JIANG Y，WANG S M，et al. Dried plasma
monitoring of meropenem and piperacillin-tazobactam in spot based LC-MS/MS method for monitoring of merope‐
the Singapore critically ill population：a prospective，multi- nem in the blood of treated patients[J]. Molecules，2022，
center，observational study（BLAST 1）[J]. J Crit Care， 27（6）：1991.
2022，68：107-113. [46] MARTENS-LOBENHOFFER J，MONASTYRSKI D，
[35] DRÄGER S，VON ROTZ M，LABHARDT N D，et al. TRÖGER U，et al. Stability of meropenem in plasma ver‐
Early target attainment with continuous infusion merope‐ sus dried blood spots（DBS）[J]. J Pharm Biomed Anal，
nem and piperacillin/tazobactam and utilization of thera‐ 2019，170：279-284.
peutic drug monitoring in critically ill patients：a retrospec‐ [47] GIJSEN M，FILTJENS B，ANNAERT P，et al. Merope‐
tive cohort study from 2017 to 2020[J]. Open Forum In‐ nem stability in human plasma at －20 ℃：detailed assess‐
fect Dis，2023，10（4）：ofad143. ment of degradation[J]. Antibiotics（Basel），2021，10
[36] SCHOENENBERGER-ARNAIZ J A，AHMAD-DIAZ F， （4）：449.
MIRALBES-TORNER M，et al. Usefulness of therapeutic [48] MORTENSEN J S，JENSEN B P，DOOGUE M. Preana‐
drug monitoring of piperacillin and meropenem in routine
lytical stability of flucloxacillin，piperacillin，tazobactam，
clinical practice：a prospective cohort study in critically ill meropenem，cefalexin，cefazolin，and ceftazidime in thera‐
patients[J]. Eur J Hosp Pharm，2020，27（e1）：e30-e35. peutic drug monitoring：a structured review[J]. Ther Drug
[37] ZYRYANOV S，BONDAREVA I，BUTRANOVA O，et al.
Monit，2022，44（6）：709-719.
Population PK/PD modelling of meropenem in preterm [49] DAILLY E，BOUQUIÉ R，DESLANDES G，et al. A li-
newborns based on therapeutic drug monitoring data[J].
quid chromatography assay for a quantification of doripe‐
Front Pharmacol，2023，14：1079680.
nem，ertapenem，imipenem，meropenem concentrations in
[38] WU Y E，XU H Y，SHI H Y，et al. Carbapenem-resistant human plasma：application to a clinical pharmacokinetic
Enterobacteriaceae bloodstream infection treated success‐
study[J]. J Chromatogr B Analyt Technol Biomed Life
fully with high-dose meropenem in a preterm neonate[J].
Front Pharmacol，2020，11：566060. Sci，2011，879（15/16）：1137-1142.
[50] RUBINO C M，BHAVNANI S M，LOUTIT J S，et al.
[39] SHEKAR K，ROBERTS J A，MCDONALD C I，et al. Se‐
Single-dose pharmacokinetics and safety of meropenem-
questration of drugs in the circuit may lead to therapeutic
failure during extracorporeal membrane oxygenation[J]. vaborbactam in subjects with chronic renal impairment[J].
Antimicrob Agents Chemother，2018，62（3）：e02103-17.
Crit Care，2012，16（5）：R194.
[40] GIJSEN M，DREESEN E，ANNAERT P，et al. Merope‐ [51] BIELECKA-ODER A. Safety and security regulations
against biological threats[M]. Dordrecht：Springer Nether‐
nem pharmacokinetics and target attainment in critically
lands，2018：151-176.
ill patients are not affected by extracorporeal membrane
oxygenation：a matched cohort analysis[J]. Microorgan- [52] UDY A A，VARGHESE J M，ALTUKRONI M，et al. Sub‐
isms，2021，9（6）：1310. therapeutic initial β-lactam concentrations in select criti‐
[41] LEE J H，LEE D H，KIM J S，et al. Pharmacokinetics and cally ill patients：association between augmented renal
Monte Carlo simulation of meropenem in critically ill clearance and low trough drug concentrations[J]. Chest，
adult patients receiving extracorporeal membrane oxygena- 2012，142（1）：30-39.
tion[J]. Front Pharmacol，2021，12：768912. [53] HITES M，TACCONE F S，WOLFF F，et al. Case-control
[42] ABDULLA A，EWOLDT T J，HUNFELD N M，et al. The study of drug monitoring of β-lactams in obese critically
effect of therapeutic drug monitoring of beta-lactam and ill patients[J]. Antimicrob Agents Chemother，2013，57
fluoroquinolones on clinical outcome in critically ill pa‐ （2）：708-715.
tients：the DOLPHIN trial protocol of a multi-centre ran‐ [54] ALOBAID A S，BRINKMANN A，FREY O R，et al.
domised controlled trial[J]. BMC Infect Dis，2020， What is the effect of obesity on piperacillin and merope‐
20（1）：57. nem trough concentrations in critically ill patients? [J]. J
[43] ABDULLA A，DIJKSTRA A，HUNFELD N G M，et al. Antimicrob Chemother，2016，71（3）：696-702.
Failure of target attainment of beta-lactam antibiotics in [55] DE WAELE J J，CARRETTE S，CARLIER M，et al.
critically ill patients and associated risk factors：a two- Therapeutic drug monitoring-based dose optimisation of
center prospective study（EXPAT）[J]. Crit Care，2020，24 piperacillin and meropenem：a randomised controlled trial
（1）：558. [J]. Intensive Care Med，2014，40（3）：380-387.
[44] SCHARF C，LIEBCHEN U，PAAL M，et al. The higher [56] ROBATEL C，BUCLIN T，ECKERT P，et al. Determina‐

中国药房 2025年第36卷第16期 China Pharmacy 2025 Vol. 36 No. 16 · 1965 ·